Edwards Lifesciences Corporation (NYSE:EW) Receives $100.27 Average Price Target from Brokerages

Shares of Edwards Lifesciences Corporation (NYSE:EW) have been given an average rating of “Moderate Buy” by the twenty-three brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $100.2727.

EW has been the subject of a number of recent analyst reports. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. UBS Group assumed coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price objective for the company. Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 620 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the transaction, the vice president owned 40,411 shares of the company’s stock, valued at approximately $3,278,948.54. The trade was a 1.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 44,158 shares of company stock worth $3,742,330. 0.31% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently modified their holdings of EW. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after purchasing an additional 23,514 shares in the last quarter. Norges Bank purchased a new stake in Edwards Lifesciences during the fourth quarter valued at $803,686,000. TD Asset Management Inc lifted its position in Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after purchasing an additional 47,051 shares during the last quarter. Intech Investment Management LLC lifted its position in Edwards Lifesciences by 22.2% during the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after purchasing an additional 12,591 shares during the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth $1,626,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 1.7%

Shares of Edwards Lifesciences stock opened at $93.59 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences has a 1 year low of $72.30 and a 1 year high of $96.29. The firm has a market cap of $53.89 billion, a PE ratio of 53.79, a PEG ratio of 2.31 and a beta of 0.85. The company has a 50 day simple moving average of $88.38 and a two-hundred day simple moving average of $84.20.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts expect that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.